Infringement of U.S Patent Nos. 7,619,004 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics," issued November 17, 2009), 7,601,758 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics in the Treatment of Gout Flares," issued October 13, 2009), 7,820,681 ("Methods for Concomitant Administration of Colchicine and a Second Active Agent," issued October 26, 2010), 7,915,269 (same title, issued March 29, 2011), 7,964,647 ("Colchicine Compositions and Methods," issued June 21, 2011), 7,964,648 ("Methods for Concomitant Administration of Colchicine and a Second Active Agent," issued June 21, 2011), 7,981,938 ("Colchicine Compositions and Methods," issued July 19, 2011), 8,093,296 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics," issued January 10, 2012), 8,093,297 ("Methods for Concomitant Administration of Colchicine and a Second Active Agent," issued January 10, 2012), 8,097,655 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics," issued January 17, 2012), 8,415,395 ("Colchicine Compositions and Methods," issued April 9, 2013), 8,415,396 (same title, issued April 9, 2013), 8,440,721 ("Methods for Concomitant Administration of Colchicine and a Second Active Agent," issued May 14, 2013), and 8,440,722 (same title, issued May 14, 2013) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Takeda's Colcrys® (single-ingredient colchicine product, used to prevent and treat gout flares). View the complaint here.

Infringement of U.S. Patent Nos. 8,591,938 ("Liquid Compositions of Calcium Acetate," issued November 26, 2013) and 8,592,480 (same title, issued November 26, 2013) following a Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Fesenius' Phoslyra® (calcium acetate oral solution, used as a phosphate binder for the reduction of serum phosphorus in patients with end stage renal disease). View the complaint here.

The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 8,318,800 ("Solid Pharmaceutical Compositions Containing Benzofuran Derivatives," issued November 27, 2012), 8,410,167 ("Use of Dronedarone for the Preparation of a Medicament for Use in the Prevention of Cardiovascular Hospitalization or of Mortality," issued April 2, 2013), and 8,602,215 ("Methods for Reducing the Risk of an Adverse Dronedarone/Beta-Blockers Interaction in a Patient Suffering from Atrial Fibrillation," issued December 10, 2013 following a Paragraph IV certification as part of defendats' filing of an ANDA to manufacture a generic version of Sanofi's Multaq® (dronedarone, used to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation). View the Glenmark complaint here.

Infringement of U.S. Patent No. 8,518,919 ("Compositions Comprising Azelastine and Methods of Use Thereof," issued August 27, 2013) following a Paragraph IV certification as part of defendats' filing of an ANDA to manufacture a generic version of Meda's Astepro® (azelastine hydrochloride nasal spray, used to treat hay fever and allergy symptoms). View the complaint here.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.